A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections.

Trial Profile

A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Doripenem (Primary) ; Cefepime
  • Indications Bacterial infections; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Jul 2014 The primary endpoint has been changed from adverse events to number of participants with clinical cure rate at test of cure visit, according to ClinicalTrials.gov record.
    • 20 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 03 Nov 2011 Planned End Date changed from 1 Mar 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top